The Commonwealth Serum Laboratories was established in Australia in 1916.
At CSL, Corporate Responsibility is about conducting our business ethically.
We offer the broadest range of quality plasma-derived and recombinant therapies in the industry.
Seqirus opened in 2015 and is the second largest influenza company in the world.
Innovation has been in the DNA of CSL since our beginning in 1916
Our product portfolio focuses on innovation in new products
Our interim dividend for 2020 was US$0.95 per share, up 12%.
Our exceptionally strong performance is a result of the focused execution of our strategy.
Help us deliver on our promise to save lives and protect the health of people.
Diversity and inclusion are top priorities for CSL.
View our ASX announcements
Visit this page to see all of our current news releases
Popular search terms: